Nctid:
NCT00000198
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-09-05"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000019970", "term"=>"Cocaine-Related Disorders"}], "ancestors"=>[{"id"=>"D000019966", "term"=>"Substance-Related Disorders"}, {"id"=>"D000064419", "term"=>"Chemically-Induced Disorders"}, {"id"=>"D000001523", "term"=>"Mental Disorders"}], "browseLeaves"=>[{"id"=>"M19100", "name"=>"Behavior, Addictive", "relevance"=>"LOW"}, {"id"=>"M21841", "name"=>"Cocaine-Related Disorders", "asFound"=>"Cocaine-Related Disorders", "relevance"=>"HIGH"}, {"id"=>"M21837", "name"=>"Substance-Related Disorders", "relevance"=>"LOW"}, {"id"=>"M30302", "name"=>"Chemically-Induced Disorders", "relevance"=>"LOW"}, {"id"=>"M4815", "name"=>"Mental Disorders", "relevance"=>"LOW"}, {"id"=>"M14473", "name"=>"Psychotic Disorders", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Behaviors and Mental Disorders", "abbrev"=>"BXM"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Substance Related Disorders", "abbrev"=>"BC25"}]}, "interventionBrowseModule"=>{"meshes"=>[{"id"=>"D000010889", "term"=>"Piracetam"}], "ancestors"=>[{"id"=>"D000018696", "term"=>"Neuroprotective Agents"}, {"id"=>"D000020011", "term"=>"Protective Agents"}, {"id"=>"D000045505", "term"=>"Physiological Effects of Drugs"}, {"id"=>"D000018697", "term"=>"Nootropic Agents"}], "browseLeaves"=>[{"id"=>"M13780", "name"=>"Piracetam", "asFound"=>"TVS", "relevance"=>"HIGH"}, {"id"=>"M6271", "name"=>"Cocaine", "relevance"=>"LOW"}, {"id"=>"M20773", "name"=>"Neuroprotective Agents", "relevance"=>"LOW"}, {"id"=>"M21869", "name"=>"Protective Agents", "relevance"=>"LOW"}, {"id"=>"M20774", "name"=>"Nootropic Agents", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Neuroprotective Agents", "abbrev"=>"NeuroAg"}, {"name"=>"Nootropic Agents", "abbrev"=>"NootAg"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Vasoconstrictor Agents", "abbrev"=>"VaCoAg"}, {"name"=>"Central Nervous System Depressants", "abbrev"=>"CNSDep"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE1"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"primaryPurpose"=>"TREATMENT"}, "enrollmentInfo"=>{"count"=>0}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1996-10"}, "statusVerifiedDate"=>"2013-12", "completionDateStruct"=>{"date"=>"1997-10", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2015-10-05", "studyFirstSubmitDate"=>"1999-09-20", "studyFirstSubmitQcDate"=>"1999-09-20", "lastUpdatePostDateStruct"=>{"date"=>"2015-10-06", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"1999-09-21", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"1997-10", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Pulse, blood pressure"}, {"measure"=>"Adverse effects"}, {"measure"=>"High, anxiety, withdrawal"}]}, "conditionsModule"=>{"keywords"=>["cocaine"], "conditions"=>["Cocaine-Related Disorders"]}, "descriptionModule"=>{"briefSummary"=>"The purpose of this study is to evaluate the effects of IV cocaine administration in cocaine dependent subjects maintained on piracetam while they are residing in an inpatient addictions treatment research unit and to subsequently follow these patients in an eight week open label assessment of piracetam in an outpatient treatment program."}, "eligibilityModule"=>{"sex"=>"MALE", "stdAges"=>["ADULT"], "maximumAge"=>"45 years", "minimumAge"=>"21 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"Please contact site for information."}, "identificationModule"=>{"nctId"=>"NCT00000198", "briefTitle"=>"Piracetam for Treatment of Cocaine Addiction - 3", "organization"=>{"class"=>"OTHER", "fullName"=>"University of Pennsylvania"}, "officialTitle"=>"Piracetam for Treatment of Cocaine Addiction", "orgStudyIdInfo"=>{"id"=>"NIDA-00238-3"}, "secondaryIdInfos"=>[{"id"=>"K20DA000238", "link"=>"https://reporter.nih.gov/quickSearch/K20DA000238", "type"=>"NIH"}, {"id"=>"K02-00238-3"}]}, "armsInterventionsModule"=>{"interventions"=>[{"name"=>"Piracetam", "type"=>"DRUG"}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"19104 6178", "city"=>"Philadelphia", "state"=>"Pennsylvania", "country"=>"United States", "facility"=>"University of Pennsylvania", "geoPoint"=>{"lat"=>39.95233, "lon"=>-75.16379}}], "overallOfficials"=>[{"name"=>"Kyle Kampman, M.D.", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"University of Pennsylvania"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"University of Pennsylvania", "class"=>"OTHER"}, "collaborators"=>[{"name"=>"National Institute on Drug Abuse (NIDA)", "class"=>"NIH"}], "responsibleParty"=>{"type"=>"PRINCIPAL_INVESTIGATOR", "investigatorTitle"=>"Principal Investigator", "investigatorFullName"=>"Kyle Kampman", "investigatorAffiliation"=>"University of Pennsylvania"}}}}
